5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine | 1201323-97-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 英文名称: 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine
• 英文别名: MK-3328；5-Fluoro-2-(1-methyl-1H-pyrrolo(2,3-b)pyridin-5-yl)oxazolo(5,4-b)pyridine；5-fluoro-2-(1-methylpyrrolo[2,3-b]pyridin-5-yl)-[1,3]oxazolo[5,4-b]pyridine
• CAS: 1201323-97-8
• 化学式: C₁₄H₉FN₄O
• 分子量: 268.25
• InChiKey: WYQHKOHCTMNFAU-UHFFFAOYSA-N

物化性质

• 沸点：
  443.3±45.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  56.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-氰基-7-氮杂吲哚 在 吡啶 、 盐酸 、 1-氯-N,N,2-三甲基丙烯胺 、 水 、 sodium hydride 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine
  参考文献：
  名称：

  [EN] NOVEL SUBSTITUTED AZABENZOXAZOLES
  [FR] NOUVEAUX AZABENZOXAZOLES SUBSTITUÉS

  摘要：

  公开号：

  WO2009155017A3

文献信息

• Substituted azabenzoxazoles
  申请人：Barrow James C.

  公开号：US08530483B2

  公开（公告）日：2013-09-10

  The present invention relates to novel amyloid binding compounds of formula (I) and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET/) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds, or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: X is O or S; A and Y independently are N, or CH.

  本发明涉及式(I)的新型淀粉样蛋白结合化合物及测量该化合物效果的方法，该方法通过测量活体患者淀粉样斑块水平的变化来实现。更具体地，本发明涉及使用该发明化合物作为正电子发射断层扫描（PET）成像中的示踪剂，以研究体内脑中的淀粉样沉积物，从而诊断阿尔茨海默病。因此，本发明涉及将新型淀粉样蛋白结合化合物用作诊断工具。本发明还涉及一种测量阿尔茨海默病治疗剂临床疗效的方法。具体而言，本发明涉及新型芳基或杂环芳基取代的氮杂苯并噁唑衍生物、组成物及其治疗用途和制备该化合物或其药学上可接受的盐、溶剂或体内水解酯的过程，其中：X为O或S；A和Y独立地为N或CH。
• NOVEL SUBSTITUTED AZABENZOXAZOLES
  申请人：Barrow James C.

  公开号：US20110085985A1

  公开（公告）日：2011-04-14

  The present invention relates to novel amyloid binding compounds of formula (I) and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET/) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds, or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: X is O or S; A and Y independently are N, or CH;

  本发明涉及式(I)的新型淀粉样蛋白结合化合物，以及通过测量活体患者淀粉样斑块水平的变化来测量化合物效果的方法。更具体地，本发明涉及使用本发明的化合物作为正电子发射断层扫描（PET）成像中的示踪剂，以研究体内脑部淀粉样沉积物，以诊断阿尔茨海默病。因此，本发明涉及使用新型淀粉样蛋白结合化合物作为诊断工具。本发明还涉及一种测量阿尔茨海默病治疗剂临床疗效的方法。具体而言，本发明涉及新型芳基或杂芳基取代的氮杂苯并噁唑衍生物、组成物和治疗用途，以及制备这些化合物的过程，或其药学上可接受的盐、溶剂合物或体内水解酯，其中：X为O或S；A和Y独立地为N或CH。
• Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrilary tangles
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10022461B2

  公开（公告）日：2018-07-17

  The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

  本发明涉及式 (I) 的吡咯并吡啶化合物 或它们的药学上可接受的盐，这些化合物可能适用于 tau 聚集物、b-片状聚集物、β-淀粉样蛋白聚集物或α-突触核蛋白聚集物的成像，因此可用于阿尔茨海默氏症患者中 tau 聚集物的结合和成像。更具体地说，本发明涉及一种在正电子发射断层扫描（PET）成像中使用本发明化合物作为示踪剂的方法，以研究体内大脑中的tau沉积物，从而诊断阿尔茨海默氏症和其他以tau病理学为特征的神经退行性疾病。本发明还涉及一种测量阿尔茨海默病和其他以tau病理学为特征的神经退行性疾病治疗药物临床疗效的方法。
• [EN] NOVEL SUBSTITUTED AZABENZOXAZOLES<br/>[FR] NOUVEAUX AZABENZOXAZOLES SUBSTITUÉS
  申请人：MERCK SHARP & DOHME

  公开号：WO2009155017A3

  公开（公告）日：2010-02-18
• PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3154970B1

  公开（公告）日：2019-11-06